CAMBRIDGE, England, Dec. 8 /PRNewswire/ -- Cambridge Antibody Technology (CAT) is delighted to announce three promotions to the key management position of Vice President (VP).
Gaynor Fryers is promoted to the position of VP Business Development and will be responsible for managing CAT's business development activities. Gaynor joined CAT in 2004, and prior to her promotion, held the position of Business Development Director. Before joining CAT, Gaynor worked as Group Commercial Director at Bespak plc and held a number of business and commercial roles at Bio Products Laboratory (BPL). Gaynor has a degree in Biological Sciences from the University of Oxford and an MBA from the Manchester Business School.
Ian Anderson is promoted to the position of VP Discovery - Respiratory and Inflammation. In his new role, Ian will lead the respiratory and inflammation team within CAT's Drug Discovery department. Ian joined CAT in 1998 to establish the pharmacology group and prior to this worked at Glaxo Wellcome in a number of roles within the pharmacology and neuroscience departments. Ian holds a degree in Pharmacology from the University of Manchester and a PhD in Pharmacology from the University of London.
Andy Williams is promoted to the position VP Discovery - Programme Management where he will lead the programme management team within CAT's drug discovery department. Andy joined CAT in 1993, following a post-doctoral fellowship at the University of British Columbia in Vancouver, and has led a number of CAT's drug discovery and technology development projects. Andy has a Biochemistry degree from Kings College London and a PhD in Molecular Genetics from Queen Mary and Westfield College, University of London.
Hamish Cameron, Chief Executive at CAT, commented "CAT's progression as a world-leading biopharmaceutical company is underpinned by the knowledge and expertise of our exceptional staff. These key promotions will strengthen and broaden the capabilities and experience of our team and we are delighted to recognise the expertise of these three individuals and their contribution to CAT's ongoing success."
Cambridge Antibody Technology (CAT):
* Cambridge Antibody Technology (CAT) is a biopharmaceutical company using
its capabilities and technologies in the discovery and development of
new and innovative antibody medicines in selected therapeutic areas to
bring improvements to seriously ill patients' lives.
* CAT is a leader in the discovery and development of human therapeutic
antibodies and has an advanced proprietary platform technology for
rapidly isolating human monoclonal antibodies using phage display and
ribosome display systems. CAT has extensive phage antibody libraries,
currently incorporating more than 100 billion distinct antibodies. These
libraries form the basis for the Company's strategy to develop a
portfolio of antibody-based drugs.
* CAT is part of the AstraZeneca group of companies.
* CAT employs around 300 people and is based near Cambridge, UK and in
Palo Alto, USA.
* For more information: www.cambridgeantibody.com
Cambridge Antibody Technology
CONTACT: Rowena Gardner, Director of Communications, or, Helen Martindale,Communications Executive, both of Cambridge Antibody Technology,+44-0-1223-471-471; or Sue Charles, Tony Stephenson, or Eva Levin, all ofNorthbank Communications, Europe, +44-20-3008-7550; or Media, Brad Miles,+1- 212-477-9007, ext 17, of BMC Communications, USA, all for CambridgeAntibody Technology